GSK expands its clinical trial manufacturing capacity at dedicated CGT facility in UK Cell and Gene Therapy Catapult (CGT Catapult) says that GSK will leverage its Stevenage facility to perform GMP cell processing and accelerate its cell and gene therapy pipeline for clinical trials.
Through this agreement, GSK is looking to improve its GMP cell processing network to advance its early stage pipeline and streamline technical transfer.
“The move by a leading pharmaceutical company like GSK to establish ATMP manufacturing capabilities at the CGT Catapult facility in Stevenage highlights the UK’s globally leading position for large and smaller organizations alike to develop, manufacture and deliver cell and gene therapies,” said Matthew Durdy, CEO, CGT Catapult.
Saama, Oracle partner on integrated clinical trial technology Saama’s range of Smart applications will be integrated with the Oracle Health Sciences Clinical One platform to help users accelerate drug development.
Saama Technologies is collaborating with Oracle to integrate Saama’s smart applications with the Oracle Health Sciences Clinical One platform. The collaboration is intended to enable pharmaceutical companies and their research partners to harness artificial intelligence (AI)-driven insights to expedite clinical trials.
Saama chief strategy officer Sagar Anisingaraju spoke with Outsourcing-Pharma about the technological integration, and how advanced technologies like artificial intelligence and machine learning are transforming research.
Gilead, Merck to team up on potential HIV combo treatment The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
Gilead Sciences and Merck have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV. The intended solutions will combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people with HIV.
Islatravir and lenacapavir are potentially first-in-class medicines in late-stage clinical trials, with significant clinical data generated for both to date. Each of the medicines reportedly has a long half-life and has demonstrated activity at low dosages in clinical studies, which support development as an investigational com
The Orchestrated Customer Engagement Technology reportedly has been adopted by 140 life sciences companies (including top-10 pharma firms) in nearly 90.
IQVIA has announced its Orchestrated Customer Engagement (OCE) solution is now in use by 140 life-sciences companies located in 90 countries. The most recent to sign on, Laboratoires Thea, is an independent eye-care group in Europe.
The company reports its clients are leveraging OCE to accelerate their global digital transformation, in order to lead to more impactful interactions with customers. Customers now include AstraZeneca, Novo Nordisk, Roche, Adhera Therapeutics, Napo Pharmaceuticals, Pierre Fabre Pharmaceuticals, PruGen Pharmaceuticals, Recordati, Theramex and Zentiva.
Susan Hill, vice president and general manager of customer engagement with IQVIA, told Outsourcing-Pharma that the COVID-19 pandemic has created a need for accelerated digital adoption in pharma development firms.
(ake1150sb/iStock via Getty Images Plus) A leader from the trial solutions provider discusses how the COVID-19 pandemic has accelerated the already growing interest in remote patient monitoring.
Outsourcing-Pharma recently spoke with Stewart Whiting, chief technical officer of Current Health, about how the use of home health monitoring has evolved in the month leading up to the pandemic, its new Community by Current Health offering, and what the landscape might look like in the years ahead.
OSP: Could you please share Current Health’s perspective on the industry’s evolving acceptance and use of at-home health monitoring?
SW: At-home monitoring has been around for over a decade, but only recently have we begun to see care delivery models fundamentally shift as a result of this technology. Largely, this is because new monitoring solutions can provide far more sophisticated visibility into patient health. Paired with advances in data science, new r